225 related articles for article (PubMed ID: 26020982)
1. [BRAF inhibitor and MEK inhibitor].
Uhara H
Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
[No Abstract] [Full Text] [Related]
2. [Treatment of BRAF-mutated metastatic melanoma].
Boyles TB; Svane IM; Bastholt L; Schmidt H
Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
[TBL] [Abstract][Full Text] [Related]
3. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
4. From targeted monotherapy to combined BRAF-MEK inhibitors and integrated genome analysis for melanoma treatment.
Roukos DH; Papaloukas C; Tzaphlidou M
Future Oncol; 2013 Jan; 9(1):5-8. PubMed ID: 23252557
[No Abstract] [Full Text] [Related]
5. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic targets in melanoma: map kinase pathway.
Haluska FG; Ibrahim N
Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
[TBL] [Abstract][Full Text] [Related]
7. [Melanoma].
Uhara H
Gan To Kagaku Ryoho; 2016 Apr; 43(4):404-7. PubMed ID: 27220785
[TBL] [Abstract][Full Text] [Related]
8. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
Gutzmer R
J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
[No Abstract] [Full Text] [Related]
9. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
10. BRAF signaling and targeted therapies in melanoma.
Dhomen N; Marais R
Hematol Oncol Clin North Am; 2009 Jun; 23(3):529-45, ix. PubMed ID: 19464601
[TBL] [Abstract][Full Text] [Related]
11. Resistance to BRAF/MEK Inhibition in Melanoma Is Mediated by the Androgen Receptor.
Cancer Discov; 2022 Aug; 12(8):1835. PubMed ID: 35748587
[TBL] [Abstract][Full Text] [Related]
12. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
Long G
Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
[No Abstract] [Full Text] [Related]
14. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
15. Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis.
Zhao CY; Chou S; Liu RC; Fernandez-Peñas P
Pigment Cell Melanoma Res; 2018 Mar; 31(2):341-344. PubMed ID: 29131505
[No Abstract] [Full Text] [Related]
16. Targeting BRAF in melanoma: biological and clinical challenges.
Mandalà M; Voit C
Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
[TBL] [Abstract][Full Text] [Related]
17. BRAF in melanoma: current strategies and future directions.
Salama AK; Flaherty KT
Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
[TBL] [Abstract][Full Text] [Related]
18. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.
Adamopoulos C; Ahmed TA; Tucker MR; Ung PMU; Xiao M; Karoulia Z; Amabile A; Wu X; Aaronson SA; Ang C; Rebecca VW; Brown BD; Schlessinger A; Herlyn M; Wang Q; Shaw DE; Poulikakos PI
Cancer Discov; 2021 Jul; 11(7):1716-1735. PubMed ID: 33568355
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerance of BRAF and MEK inhibitors on metastatic melanoma carrying the orphan pV600_K601 delinsE mutation of the BRAF gene.
Barbé J; Garnier M; Tallet A; Collin C; Leducq S; Routier É; Machet L; Samimi M
Int J Dermatol; 2021 Jul; 60(7):e283-e284. PubMed ID: 33734441
[No Abstract] [Full Text] [Related]
20. Treatment of BRAF inhibitor-induced hyperkeratosis.
Battley JE; Lenihan E; Redmond HP; Murphy M; Power DG
Acta Oncol; 2013 May; 52(4):874-7. PubMed ID: 22998476
[No Abstract] [Full Text] [Related]
[Next] [New Search]
